Propanc Biopharma Inc (OTCMKTS:PPCB) Stock Gains Momentum: Here is Why
A company that may well be worth tracking at this point in time is Propanc Biopharma Inc (OTCMKTS:PPCB) given the sort of work it is involved in. The company is working on the development of a unique approach that would help in preventing the metastasis and recurrence of solid tumors.
The company seeks to accomplish this through the use of pancreatic proenzymes which target and then eradicate cancer stem cells in patients suffering from different times of cancers. Last month on March 28 the company had been in the news after it announced that PRP had the capability of helping with pancreatic cancer treatment by suppressing TGF-β pathway and the tumor microenvironment.
The whole thing was explained by one of the company’s joint researchers. The researcher in question was Belen Toledo Cutillas, who worked at the laboratory of Professor Macarena Perán, PhD, University of Jaén in Spain.
TGF-β is a growth factor molecule and is mainly involved in cell proliferation. The Chief Scientific Officer at Propanc, Dr. Julian Kenyon spoke about the development as well. He noted that the latest studies indicated that PRP had a major effect on the microenvironment of the tumour.